Advancing Precision Medicine in High-Risk Breast Cancer: BRCA Mutations, Triple-Negative, and HR+/HER2– Subtypes - Episode 5

Role of PARP Inhibitors in Somatic BRCA Mutations and Data Update for PARP Inhibitors

,

Panelists discuss how recent data inform their approach to PARP inhibitor use in the metastatic setting, exploring the role of PARP inhibition for somatic BRCA mutations and strategies for managing PALB2 and other homologous recombination deficiency mutations.

EP. 1: NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer
EP. 2: Adjuvant CDK 4/6 Inhibitors for High-Risk HR+/HER2– Early Breast Cancer: Toxicity Management and Real-World Data
EP. 3: BRCA Testing in Early-Stage and Metastatic Breast Cancer
EP. 4: OlympiA: Data Updates From SABCS 2024
Now Viewing
EP. 5: Role of PARP Inhibitors in Somatic BRCA Mutations and Data Update for PARP Inhibitors
EP. 6: KN-522: Clinical Implications and Insights Into Clinical Practice
EP. 7: Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
EP. 8: SABCS 2024: Promising Studies in HR+ and HER2– mBC and Early-Stage TNBC

Video content above is prompted by the following:

  1. Dr. Degen asks Dr. Shatsky: In the metastatic setting, how do recent data inform your approach to PARP inhibitor use?
    1. What are your thoughts on PARP inhibition for somatic BRCA mutations?
    2. How do you approach PALB2 and other homologous recombination deficiency mutations?